SOURCE: Novo Nordisk A/S

October 05, 2009 07:13 ET

Novo Nordisk: Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - October 5, 2009) - Novo Nordisk A/S - Share repurchase programme


On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 28 September 2009, the following transactions have been made under the programme:


                  Number of     Average     Transaction
                    shares   purchase price  value, DKK
Accumulated, last
 announcement     2,682,500                 853,849,597
28 September 2009    70,000        320.8900  22,462,300
29 September 2009    59,500        321.9410  19,155,490
30 September 2009    75,000        318.8990  23,917,425
1 October 2009       75,000        317.6710  23,825,325
2 October 2009       70,000        319.9301  22,395,107
Accumulated under
 the programme    3,032,000                 965,605,244


With the transactions stated above, Novo Nordisk owns a total of 27,868,808 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Correction:

In the company announcement as of 28 September 2009 related to the share repurchase programme, the dates in the table were not updated properly. All numbers and ownership figures were however correct.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                 Investors:

Outside North America: Outside North America:
Mette Kruse Danielsen  Mads Veggerby Lausten
Tel: (+45) 4442 3883   Tel: (+45) 4443 7919
mkd@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com


Company Announcement no 59 / 2009


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.

Contact Information